Vorhofflimmerablation und Antikoagulation – Welches Patientenkollektiv kann profitieren?

Zusammenfassung

Die Antikoagulation bei Vorhofflimmern richtet sich nach dem CHA₂DS₂-VASc-Score. Nach einer Katheterablation ist die Antikoagulation abhängig von dem vorbestehenden CHA₂DS₂-VASc-Score. Für die orale Antikoagulation stehen ausschließlich die Coumadine und die Direkten Oralen Antikoagulantien zur Verfügung. Die Ablation ist mit einer hohen Erfolgsrate bei symptomatischen Patienten mit paroxysmalem Vorhofflimmern durchführbar.

Summary

Anticoagulation after catheter ablation of atrial fibrillation is depending on the preexisting CHA₂DS₂-VASc-Score. Only Coumadines and DOACs (Direct Oral Anticoagulants) should be administered in patients with atrial fibrillation. Due to the guidelines catheter ablation is prooving to be effective in symptomatic patients with paroxysmal atrial fibrillation.

Key words

Catheter ablation - anticoagulation - Coumadin - DOAK

• Literatur

• 1 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
• 2 Winkle RA, Mead RH, Engel G, Patrawala RA. Long term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 2011; 162: 193-200
• 3 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272
• 4 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747
• 5 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow up, definitions, endpoints, and research trial design. Europace 2012; 14: 1385-1385
• 6 Calkins H, Brugada J, Packer DL et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm 2007; 4: 1-1
• 7 Camm AJ et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012; 14: 1385-1413
• 8 Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8: 157-176
• 9 Verma A, Macle L, Cox J et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/flutter. Can J Cardiol 2011; 27: 60-66
• 10 Marrouche NF, Wilber D, Hindricks G et al. Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation. The DECAAF Study. JAMA 2014; 311: 498-506
• 11 Page SP, Siddiqui MS, Finlay M et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?. J Cardiovasc Electrophysiol 2011; 22: 265-270
• 12 Packer DL et al. HRS CABANA Investigators Meeting. 2013;
• 13 Packer DL, Kowal RC, Wheelan KR et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013; 61: 1713-1723
• 14 Kuck K et al. GAP-AF study helps to define optimal approach to ablation/ SARA study shows ablation superior to drugs for patients with persistent AF. ESC 2013; Athens
• 15 Kirchhof P, Fetsch T, Hanrath P et al. Targeted pharmacological reversal of electrical remodeling after Cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005; 150: 899-899
• 16 Stabile G, Bertaglia E, Senatore G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221
• 17 Lakkireddy D, Reddy YM, Di Biase L et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective register. J Am Coll Cardiol 2012; 59: 1168-1174
• 18 Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046
• 19 Garnock-Jones KP et al. Dabigatran etexilate. A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011; 11: 57-72
• 20 Eitel C, Koch J, Sommer P et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013; 15: 1587-1593
• 21 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
• 22 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med 2009; 361: 1139-1151
• 23 Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY® trial. N Engl J Med 2010; 363: 1875-1876
• 24 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
• 25 Granger CB et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
• 26 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891
• 27 Themistoclakis S, Corrado A, Marchlinski FE et al. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation. J Am Coll Cardiol 2010; 55: 735-743
• 28 Bunch TJ et al. Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke and Dementia Similar to Patients without Atrial Fibrillation. J Cardiovasc Electrophysiol 2011; 22: 839-845
• 29 Bunch TJ, Crandall BG, Weiss JP et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CADS2 score. Heart Rhythm 2013; 10: 1272-1277
• 30 Winke RA, Mead RH, Engel G et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268
• 31 Providência R, Albenque JP, Combes S et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-335
• 32 Reddy VY, Doshi SK, Sievert H et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127: 720-729
• 33 Holmes DR et al. Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL). ACC 2013; San Francisco